Loading...
•
Jan 02
STAAR Surgical Q4 2025 Earnings Report
STAAR Surgical reported fourth quarter 2025 results with year-over-year revenue growth and improved profitability, though it remained in a net loss position.
Key Takeaways
Fourth quarter 2025 net sales increased 18.1% year-over-year to 57801000, driven primarily by growth in China. Gross margin expanded significantly to 75.7%, while net loss narrowed to 18309000 compared to the prior year period.
Net sales grew 18.1% year-over-year to 57801000, primarily driven by China.
Gross margin expanded to 75.7% from 64.7% in the prior year quarter.
Net loss improved to 18309000 from 34228000 year-over-year.
Adjusted EPS excluding restructuring, impairment and related charges improved by 0.24 per share versus GAAP.
Revenue by Geographic Location
Forward Guidance
The company expressed confidence in returning to modest growth in China and progressing toward sustained profitability in 2026 following inventory normalization and improved in-market demand.
Positive Outlook
- Expect modest growth in in-market volume demand in China.
- Anticipate net sales growth in China driven by rising average selling prices.
- EVO+ ICL launch in China gaining traction.
- Improved ability to track and manage channel inventory.
- Clear path toward sustained profitability and growth.
Challenges Ahead
- Recent uncertainty from terminated Alcon merger impacted distributor behavior.
- Inventory returns in China reduced fourth quarter net sales.
- Sales outside China impacted by merger-related uncertainty.
- Exposure to foreign currency fluctuations.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...